A. Câmpeanu *, Diana Nistorescu *, V. Teodorescu *
* Prof. Dr. Alexandru Câmpeanu, Dr. Diana Nistorescu, Dr. V. Teodorescu – Clinica Medicală Spitalul Caritas – UMF București
Abstract
It had been studied 20 patients (pts) with stable angina (18 m + 2 f, mean age 59 + 7 years), without heart failure, and free of other antiischemic treatment. Frequency of anginal episodes, heart rate, blood pressure, number and severity of silent ischemia episodes (detected by 24-hours Holter monitoring) and exercise capacity (cicloergomety) had been performed, before and 4-weeks after oral terapy with Talinolol (T), 50 – 150 mg/day. T dureased anginal episodes (6,1 ± 1,2 to 1,5 ± 1/week, p < 0,05) silent ischemia episodes (10 vs. 16/24 hours) and both hourly duration (4,98 min v.s. 6,83 min; p<0,05), and daily duration (102 min/24 h vs. 324 min/24 hours). T also decreased duration of morning time ischemia (10,7 min, vs. 13,1 min) T significantly improved ischemic threshold (65,0 ± 55,0 b/min, v.s. 116,5 ± 15,1 b/min, p<0,01) and reduced S’r deppression (p<0,01), mean heart rate (p<0,05) and double product (heart rate X systolic blood pressure, p<0,01). Exercise capacity has not been affected (W = 168 vs. 156). Bradicardia (48 b/ min) was the single encountered side-effect. Conclusions: T is a cardioselective beta-adrenoreceptor blockers with significant antiischemic effect, reducing the frequency , duration and severity of silent and symptomatic ischemia episodes, by decreasing of sympato-adrenergic influences on the heart and decreasing oxigen myocardial consumption.